WallStSmart

Merck & Company Inc (MRK)vsStrata Critical Medical, Inc. (SRTA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 28673% more annual revenue ($65.77B vs $228.58M). SRTA leads profitability with a 20.6% profit margin vs 13.6%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 3.3Quality: 4.8
Piotroski: 2/9

SRTA

Hold

49

out of 100

Grade: D+

Growth: 6.7Profit: 3.5Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-13.8%)

Margin of Safety

-13.8%

Fair Value

$97.84

Current Price

$112.37

$14.53 premium

UndervaluedFair: $97.84Overvalued
SRTAUndervalued (+60.7%)

Margin of Safety

+60.7%

Fair Value

$11.33

Current Price

$5.47

$5.86 discount

UndervaluedFair: $11.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$277.36B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

SRTA3 strengths · Avg: 8.3/10
Profit MarginProfitability
20.6%9/10

Keeps 21 of every $100 in revenue as profit

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
24.1%8/10

Revenue surging 24.1% year-over-year

Areas to Watch

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

SRTA4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$462.05M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-6.3%2/10

ROE of -6.3% — below average capital efficiency

Free Cash FlowQuality
$-1.93M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SRTA

The strongest argument for SRTA centers on Profit Margin, Price/Book, Revenue Growth. Profitability is solid with margins at 20.6% and operating margin at -2.5%. Revenue growth of 24.1% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Bear Case : SRTA

The primary concerns for SRTA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while SRTA is a growth play — different risk/reward profiles.

SRTA carries more volatility with a beta of 2.15 — expect wider price swings.

SRTA is growing revenue faster at 24.1% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 49/100). SRTA offers better value entry with a 60.7% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Strata Critical Medical, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company is headquartered in New York, New York.

Want to dig deeper into these stocks?